Forte Biosciences is a biopharmaceutical company that is developing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially autoimmune applications in such indications as graft-versus-host disease, vitiligo and alopecia areata. The FBRX average annual return since 2017 is shown above.
The Average Annual Return on the FBRX average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether FBRX average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the FBRX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|